Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
News|Videos|September 29, 2025
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results from Phase 3 EMPOWER-Lung 3 Part 2 Trial
Author(s)Bruna Pellini, MD
Expert reviews favorable efficacy and durability 5-year results for cemiplimab plus chemotherapy versus chemotherapy in the EMPOWER-Lung 3 Part 2 trial.
Advertisement
Advertisement
Related to this article
Phase 1 data show that dibotatug produced a 60% overall response rate with a favorable safety profile in large granular lymphocytic leukemia.
The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML.
The FDA extended the review period for zanzalintinib plus atezolizumab in metastatic colorectal cancer.
Prophylactic tocilizumab before step-up dosing lowered CRS rates approximately 5-fold with teclistamab and talquetamab in relapsed/refractory myeloma.
Rusfertide preserved efficacy and safety benefits over placebo in both low- and high-risk polycythemia vera.
In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.
Roswell Park Comprehensive Cancer Center broke ground on an expansion of the Roswell Park Broadview Community Outreach and Engagement Center.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Daraxonrasib in Pancreatic Cancer
2
Time-Limited Pirtobrutinib-Based Triplet Yields High Rates of Undetectable MRD in First-Line CLL
3
SERENA-4 Misses Primary PFS End Point With Camizestrant Plus Palbociclib in First-Line ER+ Advanced Breast Cancer
4
Anselamimab Misses Overall Primary End Point but Reduces Mortality in Kappa AL Amyloidosis
5